Table 2:

Cohort Demographics for Patients with No ICS History and ≥1 Prior ED Visit

Variable	Overall cohort (n=1815 visits*) (%)	Received ICS+ prescription (n=121, 7%) (%)	Did not receive ICS+ prescription (n=1694, 93%) (%)
Female sex	53.9	56.2	53.8
Age Category
18-39 years	41.0	38.8	41.2
40-64 years	44.0	45.5	43.9
65 years and older	15.0	15.7	15.0
Race/Ethnicity
Black or African American	50.5	57.9	49.9
White	5.8	4.1	6.0
Hispanic	35.4	32.2	35.7
Asian	1.5	0.8	1.5
Other	6.8	5.0	6.9
Primary Language
English	93.9	95.0	93.8
Insurance Type
Medicaid	47.8	52.9	47.4
Medicare	17.9	16.5	18.0
Private	21.5	18.2	21.8
None/Uninsured	9.0	5.8	9.3
Other	3.8	6.6	3.5
Smoking status
Current or former smoker	26.9	27.3	26.9
Charlson Comorbidity Score
2 or more	15.5	16.5	15.5
Primary Care Provider
Documented in Electronic Health Record	57.2	59.5	57.0
Medications received in ED
Received SABA& in ED	93.6	91.7	93.7
Received oral steroid in ED	75.7	76.0	75.7
Received ICS+ in ED	3.6	16.5	2.7
Discharge prescription for oral steroid	69.3	80.2	68.5
Discharge prescription for SABA &	61.3	79.3	60.0
Ambulatory visit within 30 days	18.0	24.0	17.5
ED revisit within 30 days	7.4	9.1	7.3

^*There were 1815 visits among 870 unique patients.

⁺ICS = Inhaled Corticosteroid

^&SABA = Short Acting Beta Agonist